Piramal Enterprises has received approval from US Food and Drug Administration (USFDA) for its investigational new drug (IND), P11187, which aims to target diabetes. This will enable the company to initiate a Phase I clinical trial of new chemical entity (NCE) in healthy volunteers in the US.
It is a potential therapeutic target for Type 2 Diabetes Mellitus (T2DM). T2DM is an emerging worldwide health crisis with an incidence rate of 300 million by 2025 as predicted by the WHO and accounts for about 90 per cent of the diabetic population.
Piramal Healthcare, formerly known as Nicholas Piramal, is one of the largest pharmaceutical companies in India. Being part of Piramal Group, its healthcare division contributes 50% to group’s revenue.
| Company Name | CMP |
|---|---|
| Bajaj Finance | 950.20 |
| Shriram Finance | 960.00 |
| Aditya Birla Capital | 348.10 |
| Chola Invest & Fin. | 1638.30 |
| Tata Capital | 328.05 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: